Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJSD5W)

• Drug Name: FK-070 Drug Info
• Synonyms: KDI-792; Kdi 792; FK 070; FK-070; AC1O5X7F; SCHEMBL8657761; JGCFJVFIRFTRKJ-YOLZMAEBSA-N; 130047-30-2; FR-121070; 167678-84-4; (2S,4R)-2-[(Z)-5-carboxy-1-pentenyl]-4-(4-chlorophenylsulfonylamino)-1-(3-pyridylmethyl)pyrrolidine hydrochloride; 5-Hexenoic acid, 6-((2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1-(3- pyridinylmethyl)-2-pyrrolidinyl)-, monohydrochloride, (5Z)-; 178895-18-6; (Z)-6-[(2S,4R)-4-[(4-chlorophenyl)sulfonylamino]-1-(pyridin-3-ylmethyl)pyrrolidin-2-yl]hex-5-enoic acid hydrochloride

Indication

Disease Entry	ICD 11	Status	REF
Angina pectoris	BA40	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 6442424
  CAS Number: CAS 130047-30-2
  TTD Drug ID: DMJSD5W

Molecule-Related Drug Atlas

Drug(s) Targeting Thromboxane A2 receptor (TBXA2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alprostadil	DMWH7NQ	Aorta coarctation		Approved	[2]
Ridogrel	DMWH9CN	Acute myocardial infarction	BA41	Approved	[3]
LAROPIPRANT	DM5FABJ	Coronary heart disease	BA80.Z	Phase 4	[4]
Ramatroban	DMB8UQ3	Perennial allergic rhinitis	CA08.03	Phase 2/3	[5]
KP-496	DMCO8UZ	Asthma	CA23	Phase 2	[6]
TAK-128	DMHPEFS	Diabetic neuropathy	8C0Z	Phase 2	[7]
Ifetroban sodium	DMZP84Y	Thrombosis	DB61-GB90	Phase 2	[8]
Ifetroban	DMEV39E	Aspirin-induced asthma	CA23.20	Phase 2	[9]
YM-57158	DMS31YW	Allergic rhinitis	CA08.0	Phase 1	[10]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[11]

Drug(s) Targeting Thromboxane-A synthase (TBXAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PYRIDINE	DMF8CJ9	N. A.	N. A.	Phase 4	[12]
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[13]
E-6700	DMUWJI4	Asthma	CA23	Phase 2	[14]
EV-077	DM1FCDH	Type-2 diabetes	5A11	Phase 2	[15]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[11]
NV-52	DM0UOA9	Inflammatory bowel disease	DD72	Phase 1	[16]
Satigrel	DM4LSJ2	Thrombosis	DB61-GB90	Discontinued in Preregistration	[17]
MILACAINIDE TARTRATE	DMJLNUD	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[18]
Imitrodast	DMQ2ULV	Asthma	CA23	Discontinued in Phase 2	[19]
Rolafagrel	DM8Q7XV	Nephritis	GB40	Discontinued in Phase 2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thromboxane A2 receptor (TBXA2R)	TT2O84V	TA2R_HUMAN	Modulator	[1]
Thromboxane-A synthase (TBXAS1)	TTKNWZ4	THAS_HUMAN	Modulator	[1]

References

• [1] Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
• [2] Flow after prostaglandin E1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments. Invest Ophthalmol Vis Sci. 1999 Oct;40(11):2622-6.
• [3] Chronic ouabain treatment exacerbates blood pressure elevation in spontaneously hypertensive rats: the role of vascular mechanisms. J Hypertens. 2009 Jun;27(6):1233-42.
• [4] Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydroc... J Med Chem. 2007 Feb 22;50(4):794-806.
• [5] Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7.
• [6] Effects of KP-496, a novel dual antagonist for leukotriene D4 and thromboxane A2 receptors, on contractions induced by various agonists in the guinea pig trachea. Allergol Int. 2006 Dec;55(4):403-10.
• [7] ClinicalTrials.gov (NCT00229437) Efficacy and Safety Study of TAK-128 in Treating Subjects With Diabetic Peripheral Neuropathy. U.S. National Institutes of Health.
• [8] AT-1 receptor antagonism modifies the mediation of endothelin-1, thromboxane A2, and catecholamines in the renal constrictor response to angiotensin II. Kidney Int Suppl. 2005 Jan;(93):S3-9.
• [9] Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115.
• [10] In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors. J Pharmacol Exp Ther. 1998 Nov;287(2):633-9.
• [11] G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
• [12] Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
• [13] The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
• [14] Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
• [15] Company report (Pharmaceuticalintelligence)
• [16] Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
• [17] Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
• [18] Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
• [19] RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.
• [20] Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10.